By Fineline Cube 
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the Phase III BaxHTN clinical trial. This significant milestone highlights the potential of baxdrostat as a novel treatment option for patients with hypertension.
BaxHTN Trial Design and Results
The BaxHTN trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase III study. It evaluated the safety, tolerability, and efficacy of baxdrostat in two patient populations: those with uncontrolled blood pressure despite treatment with two different antihypertensive medications, and patients with treatment-resistant hypertension taking three or more antihypertensive drugs (including a diuretic). When added to standard therapy, both doses of baxdrostat (2mg and 1mg) demonstrated statistically significant and clinically meaningful reductions in mean seated systolic blood pressure (SBP) compared to placebo after 12 weeks of treatment.
Mechanism of Action
Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI). It targets the hormone responsible for elevating blood pressure and increasing cardiovascular and renal risks. This innovative mechanism positions baxdrostat as a promising new approach in the management of hypertension.
Ongoing Clinical Investigations
AstraZeneca is continuing to investigate baxdrostat through various clinical studies. These include trials for hypertension and primary aldosteronism monotherapy, as well as combination therapy with dapagliflozin for chronic kidney disease and heart failure prevention in high-risk hypertensive patients.-Fineline Info & Tech